Ceftazidime

證據等級: L5

預測適應症: 10 個

Rank 1 prediction (polyclonal hyperviscosity syndrome) is mechanistically implausible — a β-lactam antibiotic has zero relevance to immunoglobulin-mediated conditions.
Rank 4 prediction (UTI) carries the highest evidence (L2, 17 trials, 20 papers) and is actually Ceftazidime’s globally established indication — the data gap is in the Taiwan registry, not in clinical evidence.
All safety fields are [Data Gap].
Ceftazidime is not antineoplastic — the Cytotoxicity section will be omitted.

Ceftazidime: From Third-Generation Cephalosporin to Urinary Tract Infection

One-Sentence Summary

Ceftazidime is a third-generation cephalosporin β-lactam antibiotic with strong bactericidal activity against Gram-negative pathogens — including Pseudomonas aeruginosa — that is globally established for serious bacterial infections but currently absent from the Taiwan regulatory database. Although TxGNN’s highest-ranked prediction is polyclonal hyperviscosity syndrome, this has been assessed as mechanistically implausible (Evidence Level L5, Hold); the most evidence-supported and actionable prediction is Urinary Tract Infection, backed by 17 clinical trials and 20 publications at Evidence Level L2.

⚠️ Editorial Note: Ceftazidime is FDA-approved and EMA-approved for UTI in most major jurisdictions. The Taiwan system’s prediction of UTI as a “new” indication reflects a regulatory data gap, not a genuine repurposing scenario. This report is therefore better characterized as a market introduction evaluation rather than a classic drug repurposing case.

Quick Overview

Item	Content
Original Indication	No Taiwan regulatory records; globally established for serious bacterial infections (UTI, pneumonia, septicemia, meningitis, febrile neutropenia)
Predicted New Indication	Urinary Tract Infection (rank 4; highest evidence — see note below)
TxGNN Prediction Score	99.41% (UTI, rank 4)
Evidence Level	L2
US Market Status	Not marketed (Taiwan database shows 未上市; Ceftazidime IS approved in the US as Fortaz®/Tazicef®)
Number of NDAs	0 (Taiwan records only)
Recommended Decision	Proceed with Guardrails

† TxGNN rank 1 (polyclonal hyperviscosity syndrome, 99.51%) and ranks 2–3 (hyperamylasemia, congenital analbuminemia) have been evaluated and rejected as model artifacts with no mechanistic basis. Rank 6 (Ureaplasma urethritis) is directly contraindicated — Ureaplasma lacks a cell wall and is inherently resistant to all β-lactams. UTI (rank 4) is the most clinically actionable prediction in this set.

Why is This Prediction Reasonable?

Detailed mechanism of action data was not retrieved from the queried data sources for this evidence pack. Based on established pharmacological knowledge, however, Ceftazidime is a β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), ultimately causing bacteriolysis. Its antimicrobial spectrum is strongly oriented toward Gram-negative aerobic bacteria — Escherichia coli, Klebsiella pneumoniae, Proteus spp., Enterobacter spp., and critically Pseudomonas aeruginosa — which together account for the large majority of urinary tract infection (UTI) pathogens, particularly in complicated and healthcare-associated settings.

The pharmacokinetic profile of Ceftazidime is ideally suited for UTI: it is predominantly excreted unchanged by the kidneys, achieving urinary drug concentrations that are 10–100× higher than serum levels and far exceed the MIC of most susceptible uropathogens. This makes Ceftazidime especially valuable for complicated UTIs (cUTI), pyelonephritis, and catheter-associated UTIs driven by multidrug-resistant (MDR) Gram-negative organisms, for which first-line oral options are often unavailable. Its anti-Pseudomonas activity is a key differentiating feature compared to other cephalosporins.

It is important to flag an interpretive caveat: Ceftazidime’s use in UTI is not a novel repurposing — it is an established, FDA-approved indication (cUTI is a listed indication for Fortaz®). The TxGNN model predicted it for UTI because the current evidence pack has no Taiwan regulatory records for this drug, causing the system to treat a licensed indication as a new prediction. Ranks 1–3 in this set (polyclonal hyperviscosity syndrome, hyperamylasemia, congenital analbuminemia) represent spurious knowledge-graph connections with no biological plausibility and should be disregarded. The UTI evidence reviewed below therefore validates both the clinical evidence base and the drug’s suitability, rather than discovering a genuinely new therapeutic use.

Clinical Trial Evidence

(Extracted from predicted_indications[3] — Urinary Tract Infection, rank 4; 17 trials retrieved, 10 most relevant listed below)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00921024	Phase 2	Completed	129	Head-to-head double-blind RCT: IV CXA-101 vs Ceftazidime in complicated UTI including pyelonephritis — highest-relevance trial, directly evaluates Ceftazidime as active comparator in cUTI
NCT00690378	Phase 2	Completed	137	Prospective multicenter RCT: NXL104 (Avibactam) + Ceftazidime vs comparator in hospitalized adults with complicated UTI; followed by appropriate oral therapy
NCT02497781	Phase 2	Completed	97	Single-blind RCT: Ceftazidime-Avibactam vs Cefepime in children (3 months–18 years) with complicated UTI — safety, tolerability, PK, and efficacy in pediatric cUTI
NCT04882085	Phase 4	Completed	60	Open-label RCT: CAZ-AVI vs best available therapy for carbapenem-resistant Gram-negative infections in Chinese adults — infection types include cUTI, HAP, cIAI, and BSI
NCT05258851	Phase 3	Terminated	29	Non-inferiority RCT: CAZ-AVI vs Colistin for carbapenem-resistant Enterobacterales in critically ill patients; terminated early (29 of planned enrollment) — includes UTI as infection type
NCT01601093	Phase 2	Suspended	288	Ceftazidime-Sulbactam (2:1) for respiratory and urinary tract acute bacterial infection — directly tests Ceftazidime combination for UTI; currently suspended (reason unconfirmed)
NCT01430910	Phase 1	Completed	43	Two-part PK and drug-drug interaction study of Ceftazidime-Avibactam combination — provides PK basis for Ceftazidime dosing in serious infections
NCT03147807	N/A	Completed	75	BetaLACTA®-guided de-escalation from empirical carbapenems in ICU pulmonary, urinary, and bloodstream infections — Ceftazidime is a primary de-escalation target
NCT04628572	N/A	Completed	189	Retrospective real-world analysis: treatment patterns, effectiveness, and safety of CAZ-AVI in India — includes UTI among covered infection types
NCT04278404	N/A	Recruiting	5,000	Large PK/PD study for understudied drugs administered to pediatric patients per standard of care — may generate Ceftazidime-specific PK data in children with UTI

Literature Evidence

(Extracted from predicted_indications[3] — Urinary Tract Infection, rank 4; 20 publications retrieved, 10 most relevant listed below)

PMID	Year	Type	Journal	Key Findings
39817442	2025	Systematic Review / Meta-analysis	J Comparative Effectiveness Res	Network meta-analysis of treatment options for complicated UTI and acute pyelonephritis; evaluates β-lactam/β-lactamase inhibitor combinations including Ceftazidime-based regimens against carbapenems as last line
38688353	2024	Expert Consensus Review	Int J Antimicrobial Agents	Italian-French infectious disease society joint guidance on treating MDR Gram-negative bacilli; positions Ceftazidime-Avibactam as a key agent for CRE and ESBL-producing uropathogens
33618353	2021	Retrospective Cohort	Clin Infect Dis	Multicenter observational study of CAZ-AVI for KPC-producing Klebsiella pneumoniae infections; establishes real-world clinical value of Ceftazidime combinations for resistant uropathogens
32094128	2020	Comparative Cohort	Antimicrob Agents Chemother	Multicenter retrospective comparison of CAZ-AVI vs meropenem-vaborbactam for CRE infections — UTI patients excluded from primary endpoint but provides comparative efficacy context
40530972	2025	PK/PD Modeling	Antimicrob Agents Chemother	Population PK/PD modeling for aztreonam-avibactam (EU-approved for cUTI/cIAI/HAP caused by MDR Gram-negatives); methodology and dosing optimization directly applicable to Ceftazidime-based BLI combinations
35787918	2022	Review	Int J Antimicrobial Agents	Clinical evidence review for novel antibiotics against MDR Gram-negative bacteria; Ceftazidime-Avibactam featured prominently for UTI and intra-abdominal indications
39934901	2025	Systematic Review / Meta-analysis	Antimicrob Resistance & Infection Control	Global trends of CAZ-AVI resistance in Gram-negative bacteria — critical for informing appropriate patient selection and monitoring requirements
30219824	2019	Review	Clin Infect Dis	Antibiotic renal dose adjustment review; discusses reduced clinical response warnings for Ceftazidime-Avibactam in patients with creatinine clearance 30–50 mL/min — directly relevant for UTI patients with concurrent renal impairment
37873539	2023	Cross-sectional Observational	Open Medicine	Bacteriology and antibiogram of UTI in chronic kidney disease patients; confirms susceptibility profiles for Gram-negative uropathogens relevant to Ceftazidime selection
30270406	2018	Phase 3 RCT	Infectious Dis & Therapy	TANGO II: meropenem-vaborbactam vs best available therapy (including CAZ-AVI) for CRE infections — provides Phase 3 comparative efficacy context for Ceftazidime-based regimens

US Market Information

No records were found in the current database for Ceftazidime. This reflects a data gap in the Taiwan regulatory registry, not an absence of global approvals.

For reference, Ceftazidime is approved in the US under:

Brand Name	Dosage Form	Key Approved Indications (US FDA)
Fortaz®	IV / IM Injection	Complicated and uncomplicated UTI, lower respiratory tract infections, skin/soft tissue infections, bacterial septicemia, bone/joint infections, CNS infections (meningitis), intra-abdominal infections
Tazicef®	IV / IM Injection	Same indications as Fortaz® (generic/alternative brand)
Avycaz® (as CAZ-AVI)	IV Infusion	Complicated intra-abdominal infections (with metronidazole), complicated UTI including pyelonephritis, hospital-acquired/ventilator-associated bacterial pneumonia — for MDR Gram-negative organisms

Safety Considerations

Please refer to the package insert for safety information.

All safety data fields — key warnings, contraindications, and drug-drug interaction database — returned no retrievable data in this evidence pack. This is a data gap (flagged as DG001, severity: Blocking), not an absence of known safety concerns. Based on established pharmacological knowledge, clinicians should be aware that Ceftazidime carries well-characterized risks including: requirement for renal dose adjustment (creatinine clearance monitoring), risk of Clostridioides difficile-associated diarrhea, potential for seizures at supratherapeutic doses, and cross-reactivity considerations in patients with penicillin allergy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ceftazidime has a well-established pharmacological mechanism, strong renal pharmacokinetics, and multiple completed Phase 2 RCTs directly supporting efficacy in complicated UTI — including two trials where Ceftazidime served as the active comparator arm, reflecting its status as a clinical standard. The primary barrier is not clinical evidence but rather the absence of Taiwan regulatory records and safety data in the current system, both of which must be resolved before any formal indication review can proceed.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve TFDA package insert warnings and contraindications: download PDF from TFDA website and extract safety text before S1 safety screening can be completed
[DG002 — High] Obtain Mechanism of Action data via DrugBank API (DB00438) to populate the mechanistic link analysis
Clarify the regulatory pathway: this appears to be a market introduction case (Ceftazidime is already FDA/EMA approved for UTI), not a classic repurposing — confirm whether a Taiwan NDA, abbreviated NDA, or import approval is the appropriate route
Obtain complete drug-drug interaction profile from DrugBank or clinical references (e.g., interactions with nephrotoxic agents, anticoagulants)
Define a patient selection strategy: Ceftazidime’s UTI value is primarily in complicated UTI / MDR uropathogens; clear criteria should distinguish from simpler UTIs where oral agents suffice
Establish a renal function monitoring protocol: dose adjustment is mandatory for patients with CrCl < 50 mL/min, which is common in UTI populations with underlying comorbidities
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.